Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Missense mutant p53 alleles are found in nearly 40% of human tumors.
• Mutant p53 proteins (mutp53) gain oncogenic functions, promoting cancer progression, metastasis, and chemoresistance.
• Stabilized mutp53 proteins are crucial for tumor growth and survival, representing a tumor-specific vulnerability.

Purpose of the Study:

• To review current drug strategies targeting the oncogenic gain-of-function (GOF) missense mutant p53 protein.
• To highlight mutp53 as a promising cancer-specific drug target.
• To discuss preclinical development of direct mutp53 protein-targeting therapies.

Main Methods:

• Literature review of current preclinical drug development strategies.
• Analysis of molecular mechanisms underlying mutp53 stabilization and function.
• Examination of evidence from recent mouse models demonstrating tumor dependence on mutp53.

Main Results:

• Mutant p53 proteins exhibit gain-of-function (GOF) activities promoting malignancy.
• Stabilization of mutp53, protected by HSP90/HDAC6 from degradation, is essential for its GOF.
• Tumors with stabilized GOF mutp53 show dependency, creating exploitable vulnerabilities.

Conclusions:

• Mutant p53 proteins are key drivers of cancer progression and therapeutic resistance.
• Targeting stabilized mutp53 proteins represents a viable and promising cancer-specific therapeutic strategy.
• Directly targeting mutp53 protein offers potential for novel cancer treatments with improved patient survival.